Cannabis and schizophrenia: a Real-World look at the dual effects
NCT ID NCT07309159
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will follow 120 people with schizophrenia who use cannabis, using mobile phone surveys and thinking tasks to track symptoms in real time. The goal is to understand how cannabis may both worsen positive symptoms (like hallucinations) and reduce negative symptoms (like lack of motivation). The findings could help shape better care for patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- cannabis
- What this could lead to
- If successful, this study could clarify how cannabis affects schizophrenia symptoms, potentially guiding better management strategies.
- What could go wrong
- This is an early-phase observational study, not a treatment trial. Results may not lead to direct clinical changes, and cannabis use carries known risks for mental health.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZO AFFECTIVE DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new pill for schizophrenia pass its first human test?
- Can a new daily pill offer safer Long-Term control of schizophrenia?
- Can an Anti-Seizure drug quiet the brain and sharpen thinking in schizophrenia?
- Can a dissolving film tame agitation in schizophrenia?
- Can a phone app teach the brain to read social cues?
- Can a gentle brain current silence voices that medication Can't?